Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros







Base de dados
Intervalo de ano de publicação
1.
Rev. méd. Chile ; 145(1): 41-48, ene. 2017. ilus, graf, tab
Artigo em Espanhol | LILACS | ID: biblio-845502

RESUMO

Background: Encapsulating peritoneal sclerosis (EPS) is a complication of peritoneal dialysis (PD) with a low prevalence but high mortality. It is characterized by peritoneal inflammation and fibrosis with subsequent development of intestinal encapsulation. It is associated with a long lapse on PD, frequent episodes of peritonitis, high glucose solution use, and high peritoneal transport status. Aim: To report the clinical features of patients on PD, who developed EPS. Material and Methods: Review of medical records of 12 patients aged 43 ± 10 years (eight women) who developed EPS. Results: The mean time spent on PD was 98 months. The main clinical manifestations were abdominal pain in 82% and ultrafiltration failure in 63%. In 92%, there was a history of peritonitis and 75% had high peritoneal transport at the time of diagnosis. The main findings in computed tomography were peritoneal calcification and thickening. There was a biopsy compatible with the diagnosis in 10 cases. Treatment consisted in withdrawal from PD, removal of PD catheter and the use of corticoids and tamoxifen. After withdrawal from PD 50% of patients became asymptomatic. The rest had intermittent abdominal pain and altered bowel movements. Two patients died (17%). Conclusions: EPS is a serious complication of PD, which should be suspected in any patient with compatible clinical symptoms, long time on PD, multiple episodes of peritonitis and high peritoneal transport profile.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Peritonite/diagnóstico , Peritonite/etiologia , Diálise Peritoneal/efeitos adversos , Fibrose Peritoneal/etiologia , Peritonite/patologia , Peritonite/terapia , Chile , Estudos Retrospectivos , Fatores de Risco , Fibrose Peritoneal/patologia , Fibrose Peritoneal/terapia , Falência Renal Crônica
2.
Rev. méd. Chile ; 143(12): 1569-1578, dic. 2015. tab
Artigo em Espanhol | LILACS | ID: lil-774443

RESUMO

Renal involvement affects over one half of patients with Systemic Lupus Erythematosus increasing their mortality and morbidity, including chronic renal disease and the need of renal replacement therapies. Aiming to achieve a consensus in the most relevant topics on diagnosis, therapy and follow-up of patients with lupus renal disease, the Chilean Societies of Nephrology and Rheumatology constituted a workgroup that, based on a critical review of the available literature and their experience, raised and answered by consensus a set of relevant questions. This document includes aspects related to the clinical diagnosis, the importance of a suitable histological classification, therapeutic alternatives to induce and maintain disease remission, strategies for follow-up, additional therapies and ginecological-obstetric issues.


Assuntos
Humanos , Lúpus Eritematoso Sistêmico/complicações , Insuficiência Renal Crônica/etiologia , Insuficiência Renal Crônica/terapia , Chile , Consenso , Insuficiência Renal Crônica/diagnóstico
4.
Rev. méd. Chile ; 137(1): 137-177, ene. 2009. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-511858

RESUMO

The key messages of these guidel ines on chronic kidney disease are: • Chronic kidney disease (CKD) is a public health problem due to its wide distribution, high rate of complications and cost. • CKD is a common condition, its prevalence being about 10 percent, and is treatable if it is detected on time. • A patient with CKD has a higher risk of cardiovascular mortality than of progression of its underlying renal disease. • A new definition of CKD, based on estimated Glomerular Filtration Rate (eGFR) and kidney damage, facilitates its detection and management. • CKD is detected with three simple tests: 1) Blood pressure measurement, 2) Detection of proteinuria or albuminuria in an isolated urine sample, and 3) Estimation of renal function (eGFR), based on serum creatinine, age, gender and race. • The CKD risk groups are individuáis with diabetes, hypertension and a family history of renal disease. • The most cost-effective measures are to detect and treat diabetic and hypertensive patients in the community. • Therapy must emphasize the maximal reduction of cardiovascular risk. • The complications of CKD such as anemia and renal osteodystrophy can be identified and treated on time. • Most patients with chronic kidney disease are detected in the community, therefore their initial care must be organized at the level of primary care, along with programs for hypertension and diabetes.


Assuntos
Humanos , Falência Renal Crônica/diagnóstico , Falência Renal Crônica/terapia , Albuminúria/diagnóstico , Albuminúria/terapia , Chile , Complicações do Diabetes/diagnóstico , Complicações do Diabetes/terapia , Hematúria/diagnóstico , Hematúria/terapia , Hipertensão/complicações , Falência Renal Crônica/complicações , Testes de Função Renal , Proteinúria/diagnóstico , Proteinúria/terapia
5.
Rev. méd. Chile ; 136(3): 279-286, mar. 2008. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-484896

RESUMO

Background: Despite a better management of the variables that influence the development of diabetic nephropathy there is a progressive increase in the prevalence of terminal renal failure among diabetics, whose cause is not clear. Aim: To study in a group of patients in hemodialysis, the quality of diabetes control previous to the entry to dialysis, their physical condition and their evolution. Material and methods: Diabetic patients with at least three months of hemodialysis answered a questionnaire about diabetes control quality previous to dialysis and had physical and laboratory assessment. They were followed for at least four years thereafter. Results: Fifty seven patients aged 62±11 years were studied. Eighty four percent had some degree of disability. Eighty seven percent had high blood pressure and 73 percent had to enter dialysis as an emergency. Mean glycosilated hemoglobin was 7.7 percent and 58 percent had a dialysis dose with a Kt/Vofless than 1.2. Fifty eight percent died during follow up. No relationship between mortality and age, blood pressure, glycosilated hemoglobin of Kt/V, was observed. Conclusions: There is an inadequate management of blood glucose and blood pressure of diabetic patients before entry to dialysis. They are referred ¡ate to the nephrologist, the dialysis dose is insufficient and they have a high mortality.


Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Glicemia/análise , Nefropatias Diabéticas/terapia , Falência Renal Crônica/terapia , Diálise Renal , Chile/epidemiologia , Diabetes Mellitus Tipo 1/complicações , /complicações , Nefropatias Diabéticas/sangue , Nefropatias Diabéticas/mortalidade , Progressão da Doença , Seguimentos , Hemoglobinas Glicadas/análise , Falência Renal Crônica/sangue , Falência Renal Crônica/mortalidade , Diálise Renal/mortalidade , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA